Hims and Hers Health Inc vs JD.Com Inc — how do they compare? Hims and Hers Health Inc trades at $30.56 (market cap $7.35B), while JD.Com Inc trades at $31.37 (market cap $45.40B). The key difference: JD.Com Inc is far larger — about 6.2× Hims and Hers Health Inc's market cap, and JD.Com Inc pays a 2.99% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | JD | |
|---|---|---|
Market Cap | $7.35B | $45.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $36.17 |
52-Week Low | $14.52 | $25.19 |
Enterprise Value | $7.73B | $31.45B |
Dividend Yield | — | 2.99% |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.
The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.
JD.com trades at $32.97, up 0.49% with bullish technical signals and strong institutional support. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $0.74 beating expectations by 30%. Revenue grew to $1.31 trillion in 2025, though net income margin compressed to 1.05%. Analysts maintain a strong buy consensus with $39.50 price target, representing 20% upside potential.
JD offers compelling value with attractive valuation multiples (P/S 0.25, P/E 24.03) and robust cash flow generation. Key risks include regulatory scrutiny of the Ceconomy acquisition and margin pressure from competitive e-commerce markets. The upcoming Q2 2026 earnings on August 13, 2026 will be critical for confirming growth trajectory.
Trailing returns across standard periods
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →